

Atherosclerosis: Is it Time for a New Name?
José A. Páramo, Oscar Beloqui and Javier Diez

Circulation. 2001;104:e38

doi: 10.1161/01.CIR.104.7.e38

Circulation is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231

Copyright © 2001 American Heart Association, Inc. All rights reserved.

Print ISSN: 0009-7322. Online ISSN: 1524-4539

The online version of this article, along with updated information and services, is located on the World Wide Web at:

<http://circ.ahajournals.org/content/104/7/e38>

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in *Circulation* can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the [Permissions and Rights Question and Answer](#) document.

Reprints: Information about reprints can be found online at:
<http://www.lww.com/reprints>

Subscriptions: Information about subscribing to *Circulation* is online at:
<http://circ.ahajournals.org/subscriptions/>

Atherosclerosis: Is it Time for a New Name?

To the Editor:

Atherosclerosis, the leading cause of cardiovascular death in Western countries, is an inflammatory disease.¹ Evidence linking inflammation to atherosclerosis stems from studies focusing on the acute and chronic phases of coronary heart disease. Elevated acute-phase reactants and cytokine production, activation of CD4 and CD8 circulating lymphocytes, the presence of infiltrating macrophages, expression of interferon- γ , and neoangiogenesis all support the notion that atherosclerosis shares similar pathophysiological mechanisms with other inflammatory/autoimmune diseases.² Moreover, the earliest type of atherosclerotic lesion (the fatty streak) is also an inflammatory lesion, consisting of macrophages and T-lymphocytes. In addition, circulating markers of inflammation such as C-reactive protein recently have been found to be potential predictors of future cardiovascular and cerebrovascular events in patients with the disease.^{3,4} The study reported by Muhlestein et al⁵ in the October 17, 2000, issue of *Circulation* shows that high-sensitivity C-reactive protein can also be predictive for mortality in patients with coronary artery disease.

In the light of these recent pathophysiological findings, we think that time has come to reexamine the name for atherosclerosis and that a new name adapted to a more realistic scientific

language is required. In fact, arteriosclerosis is now seen as a protective rather than a detrimental mechanism in the evolution of the disease. Therefore, the undersigned authors propose the name of inflammatory and sclerosing arterial disease (ISAD), opening the possibility for other plausible nominations based on the knowledge of the inflammatory mechanisms of this disease.

José A. Páramo, MD

Oscar Beloqui, MD

Javier Diez, MD, PhD

Hematology, Cardiovascular Division and Internal Medicine

University Clinic

31080 Pamplona, Spain

1. Ross R. Atherosclerosis: an inflammatory disease. *N Engl J Med.* 1999; 340:115–126.
2. Pasceri V, Yeh ETH. A tale of two diseases: atherosclerosis and rheumatoid arthritis. *Circulation.* 1999;100:2124–2126.
3. Lagrand WK, Visser CA, Hermens WT, et al. C-reactive protein as cardiovascular risk factor. *Circulation.* 1999;100:96–102.
4. Ridker PM, Hennekens CH, Buring JE, et al. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. *N Engl J Med.* 2000;342:836–843.
5. Muhlestein JB, Horne BD, Carlquist JF, et al. Cytomegalovirus seropositivity and C-reactive protein have independent and combined predictive value for mortality in patients with angiographically demonstrated coronary artery disease. *Circulation.* 2000;102:1917–1923.